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Backgruond: Since their first description, activating epidermal growth factor receptor (EGFR) mutations identify a
distinct clinical entity of patients with non-small-cell lung cancer (NSCLC).
Findings: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease,
with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation
EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. However, after an initial response, all patients inevitably
progress and several mechanisms including a secondary mutation in exon 20 of the EGFR gene (T790M) or MET or
HER2 amplifications are responsible for acquired resistance (AR). In clinical practice few options are available for
patients with AR, and several new agents or strategies are currently under investigation, including second
generation TKIs.
Conclusions: Aim of the present review is to present available data on new EGFR-TKIs and to discuss how these
agents could overcome AR to erlotinib or gefitinib.
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In the last few years, the treatment of advanced non-
small-cell lung cancer (NSCLC) has radically changed,
due to advances in cancer biology. The old-fashioned
‘one size fits all’ chemotherapeutic approach is nowadays
replaced by a careful selection mainly based on tumor
histology and, most importantly, on biological character-
istics. Specifically, the discovery of the biologic and
therapeutic importance of acquired genetic alterations in
two genes that encode pharmacologically targetable tyro-
sine kinases, the Epidermal Growth Factor Receptor
(EGFR) and Anaplastic Lymphoma Kinase (ALK) has
changed the way these cancers are treated.
In 2004, EGFR gene mutations were firstly identified:
classical-activating EGFR mutations are localized in exon
19, mainly consisting of an in-frame deletion (45-50%),
and in exon 21, consisting of the L858R point mutation
(40-45%), even if there are less common mutations* Correspondence: f.cappuzzo@gmail.com
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reproduction in any medium, provided the origlocalized in other exons [1-3]. Since their identification,
it was clear that EGFR mutations, more frequently ob-
served in never smokers, adenocarcinoma histology,
women and Asiatic patients, outline a distinct subgroup
of NSCLC. During the last years, six phase III trials
(Table 1) established that patients harboring activating
EGFR mutations benefit more from a first line treatment
with an EGFR tyrosine kinase inhibitor (TKI), such as
erlotinib or gefitinib, than from standard chemotherapy,
at least in terms of response rate (RR), progression-free
survival (PFS) and quality of life [4-9]. On the basis of
these solid results, regulatory agencies have progressively
approved EGFR-TKIs for the first line treatment of
NSCLC harbouring activating EGFR mutations.
Unfortunately, after a median of 8–10 months, all
responding patients develop acquired resistance (AR) to
EGFR-TKI therapy, with the inevitable consequence of
disease progression. Recent studies demonstrated that
several mechanisms are responsible for AR (Figure 1),
with approximately 30% of patients in which resistance
factors are not yet identified [10]. The firstly described
and the most common event responsible for resistanceThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 First line trials of 1st generation TKI in EGFR
mutated patients
Study N OR% mPFS (mo) mOS (mo)
First Signal4
Gefitinib 26 85 8 27.2
Cis/Gem 16 38 2.1 25.6
IPASS5
Gefitinib 132 71 9.5 19
Carbo/Taxol 129 47 6.5 18
WJTOG6
Gefitinib 86 62 9.2 30.9
Cis/Doce 86 31 6.3 NR
NEJOG7
Gefitinib 114 74 10.8 27.7
Carbo/Taxol 110 31 5.4 26.6
OPTIMAL8
Erlotinib 83 83 13.1 NR
Carbo/Gem 72 36 4.6 NR
EURTAC9
Erlotinib 86 58 9.7 NR
Plat Doublet 87 15 5.2 NR
N, number of patients; OR, objective response rate; mPFS, median progression
free servival; mOS, median overall survival; mo, months; cis, cisplatin;
gem, gemcitabine; carbo, carboplatin; doce, docetaxel; plat, platinum;
NR, not reached.
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which is found in ≈ 50% of patients progressing after an
initial response to erlotinib or gefitinib [11,12]. Other
less frequent mechanisms include secondary mutations
within EGFR [13,14], MET amplification [15], HER2
amplification [16,17], small cell histologic transformation
[18]. Identification of mechanisms responsible for AR
has therapeutic implications, and several agents are cur-
rently under investigation particularly for individuals
with the secondary T790M mutation.Figure 1 Mechanisms responsible for acquired resistance (adapted froThe family of 2nd generation TKIs exploit three basic
approaches aimed at increasing the efficacy over first-
generation EGFR-TKIs and overcoming the AR, such as
intensification of EGFR inhibition, targeting a specific
alteration of the EGFR downstreaming signaling and fi-
nally combining the EGFR plus alternate pathway inhib-
ition. This review will discuss the mechanism of action,
the available data and the future implications of second-
generation EGFR-TKIs for the treatment of advanced
NSCLC.
Intensification of EGFR inhibition
EGFR mutations identify a distinct subgroup of NSCLC
characterized by oncogene addiction, for which cell’s
growth and survival signals are dependent upon EGFR
activation. In this scenario, cells would develop resist-
ance mechanisms that reactivate EGFR despite the pres-
ence of an inhibitor, as the acquired T790M second site
mutation in the exon 20 of EGFR gene. The T790M
missense mutation could be classified as the gatekeeper
mutation, occurring within the ATP-binding site and
interfering with the first-generation TKI’s binding by steric
hindrance, causing a bulky methionine side chain in
the receptor kinase domain [19]. In vitro studies showed
that exposing EGFR-mutant lung cancer cell lines to a
mutagen and culturing them in the presence of an EGFR-
TKI, the resistant clones with the T790M mutation
maintained a persistent phosphorylation [20]. Given this
role of persistent EGFR signaling, many trials evaluated
the intensification of EGFR inhibition through the use
of drug molecules with additional activity against other
receptors in the EGFR family, as the second-generation
neratinib, dacomitinib and afatinib [21]. These inhibi-
tors are mainly different from erlotinib and gefitinib
for two features: each forms a covalent and irrevers-
ible attachment to the EGFR kinase domain, and
each also inhibits other members of the ERBB family
(Figure 2).m cancerdiscovery.aacrjournals.org).
Figure 2 Epidermal Growth Factor Receptor Family and intracellular pathway (adapted from nature.com).
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Neratinib is an oral, irreversible inhibitor of both EGFR
and HER2; in preclinical studies conducted on cell lines
with both an activating EGFR mutation and the T790M,
neratinib was more effective at suppressing cell prolifer-
ation than gefitinib [22]. After a phase I trial, recruiting
heavily pretreated patients with NSCLC in which the
maximum tolerated dose (MTD) was at 320 mg daily
[23], neratinib was studied in a phase II study. During
the study, due to the development of grade 3 diarrhea in
more than 50% of patients at MTD, the dose was de-
creased to 240 mg orally daily. Unfortunately the drug
showed modest clinical efficacy with only 3% response
rate in 91 EGFR mutant patients included in a phase II
study and with no response in patients EGFR T790M
mutated [24]. The lack of efficacy could probably be re-
lated to the high concentrations of neratinib required in
preclinical studies to inhibit EGFR T790M and the limi-
tations of clinical dosing.
Dacomitinib
Dacomitinib is an irreversible EGFR, HER2 and HER4
inhibitor with a higher kinase inhibition than gefitinib/
erlotinib in both gefitinib/erlotinib-sensitive and in
EGFR-T790M and HER2-mutated cell lines [25]. After a
phase I trial, recruiting pretreated NSCLC patients and
establishing the MTD at 45 mg orally daily [26], a phase
II study, performed in patients with NSCLC after failure
of ≥ 1 chemotherapy regimen and erlotinib, showed a
promising activity and a meaningful improvements in the
patient-reported outcomes (PROs) [27]. A large phase II
study randomly assigned 188 pretreatred NSCLC to daco-
mitinb or erlotinib. In the overall population PFS, theprimary end-point of the study was 12.4 weeks for daco-
mitinib arm and 8.3 weeks for erlotinib arm; the PFS
benefit was consistent across several subgroups and par-
ticularly remarkable in patients with KRAS wild-type tu-
mors, with a median PFS of 16.1 weeks versus 8.3 weeks
in the experimental and control arm respectively [28]. The
ongoing ARCHER 1009 study, a phase III, multicenter,
double-blinded trial comparing dacomitinib to erlotinib in
pretreatred NSCLC will clarify whether new generation
EGFR-TKIs are superior to first-generation agents particu-
larly in the KRAS wild-type population [29]. A recent
study evaluated the efficacy of dacomitinib in front-line
setting in NSCLC patients with activating EGFR muta-
tions (Table 2). The study showed that dacomitinib is
particularly effective with a response rate of 74% and a
median PFS of 16.8 months [30]. Based on these data, the
ARCHER 1050, a phase III, open label trial has been de-
signed to compare the efficacy of first line dacomitinib
versus gefitinib in 440 EGFR mutant patients with stage
IIIB/IV NSCLC. The primary endpoint is PFS by Inde-
pendent Radiologic Review. This trial is ongoing, with no
data currently available [31].
Afatinib
Afatinib is an orally, irreversible EGFR, HER2 and HER4
inhibitor, showing preclinical activity against cancer cells
harboring common activating EGFR mutations and the
T790M mutation, albeit with a lower potency [32]. Phase
1 studies established the MTD at 50 mg orally daily,
with diarrhea and rash as most common adverse event
[33]. The role of afatinib in first line setting has been in-
vestigated in three studies (Table 2). The first, the LUX-
LUNG 2 trial, was a phase 2 trial exploring the efficacy
Table 2 First line trials of 2nd generation TKI in EGFR
mutated patients
N OR% mPFS (mo) mOS (mo)
Dacomitinib
Phase II trial30 92 74 17 NR
Afatinib
LUX LUNG II trial34
All EGFR mutations 129 61 10.1 24.8
Exon 19–21 mutations 106 66 13.7 38.7
LUX LUNG III trial35
All EGFR mutations
Afatinib 230 56 11.1 NR
Cis/Gem 115 23 6.9 NR
Exon 19–21 mutations
Afatinib 204 - 13.6 NR
Cis/Gem 104 - 6.9 NR
LUX LUNG VI trial39
All EGFR mutations
Afatinib 242 66.9 11.1
Cis/Gem 122 23 5.6
XL647
Phase II trial53
All EGFR mutations 41 20 5.3 19
Exon 19–21 mutations 14 57 9.3 NR
Table 3 Trials of 2nd generation TKI in acquired resistance
setting
N OR% mPFS (mo) mOS (mo)
Afatinib
LUX LUNG I trial40
Afatinib 390 7 3.3 10.8
Placebo 195 <1 1.1 12.0
LUX LUNG IV trial42 61 8.2 4.4 19
XL647
Phase II trial52 41 3 3.6 16.1
<, less than.
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NSCLC. The study, enrolling patients untreated or pre-
viously exposed to chemotherapy, was subsequently
amended to allow only untreated patients. The primary
endpoint was objective response rate by Independent
Radiologic Review. Among the 129 enrolled patients, 61
received afatinib as first-line treatment and 68 in second
line, 99 received 50 mg orally daily as starting dose and
30 received 40 mg orally daily; 106 patients presented
the common exon 19 or 21 EGFR mutations and 23 the
other less common mutations. The objective response
rate in the overall population was 61% by independent
review and 60% by investigator assessment. In the
EGFR-mutated patients, the objective response rate by
independent review was 66%, whereas was 39% in pa-
tients with uncommon EGFR mutations. Drug-related
adverse event, mainly diarrhea and skin rush were ob-
served in the vast majority of cases, with about a quarter
of patients experiencing grade 3 adverse events with
50 mg dose. These data indicated that the daily dose of
40 mg was preferable for additional studies [34]. Two
other phase III trials, in the same setting, have been sub-
sequently designed. The LUX-LUNG 3 study [35], a
multicenter, randomized, open-label phase III study
compared afatinib with cisplatin plus pemetrexed inpatients with lung adenocarcinoma, stage IIIb/IV harbor-
ing EGFR mutations [36,37]. Among the 1,269 screened
patients, 345 resulted eligible and were randomized in a
two-to-one fashion to afatinib 40 mg daily or chemother-
apy up to a maximum of six cycles (without any mainten-
ance therapy). As expected, patients were mainly East
Asian, never-smokers and women; EGFR mutations were
predominantly exon 19 deletions and L858R point muta-
tions. The PFS assessed by independent review (primary
endpoint) has been significantly prolonged in the afatinib
arm compared to chemotherapy arm, with median PFS of
11.1 and 6.9 months, and 13.6 versus 6.9 months in pa-
tients with classical (exon 19 deletion or exon 21) EGFR
mutations. Afatinib has achieved a higher response rates
compared with chemotherapy according to both inde-
pendent (56% versus 23%) and investigator (69% versus
44%) assessment, and higher disease control rate (90% ver-
sus 81% by independent review). The most frequent
(≥20% incidence) adverse reactions from afatinib were
diarrhea, rash/dermatitis acneiform, stomatitis, parony-
chia, dry skin, decreased appetite and pruritus; treatment-
related adverse events grade ≥ 3 occurred in 112 patients
(49%) receiving afatinib but therapy was discontinued just
in 8%; predose plasma samples on days 1 and 8 of cycle
two and day 1 of cycle three demonstrate that dose modi-
fication, due to individual tolerability, optimized the ex-
posure to afatinib, holding efficacious plasma levels [38].
In the third study, the LUX LUNG 6 [39], Asian patients
harbouringEGFR mutations have been randomized in a
two-to-one fashion to afatinib 40 mg daily or cisplatin plus
gemcitabine. The study showed that patients treated with
afatinib had a significantly longer PFS than individuals re-
ceiving chemotherapy (median PFS 11.0 versus 5.6
months, p < 0.0001), as well as higher response rate (66.9%
versus 23.0%, p < 0.0001) and higher disease control rate
(92.6% versus 60.2%, p < 0.0001).
Two prospective studies have investigated the role of
afatinib in patients with acquired resistance to first gen-
eration EGFR-TKIs (Table 3). The first reported trial, the
LUX LUNG 1 [40,41], randomly allocated 585 NSCLC
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tients had received one or two previous chemotherapy
regimens and had disease progression after at least 12
weeks of treatment with erlotinib or gefitinib. The me-
dian OS (primary endpoint) was not different even if a
significant difference in PFS was observed (3.3 versus 1.1
months, p < 0.0001 by independent review). In the same
setting, the LUX LUNG 4 trial [42] enrolled 62 Japanese
patients showing 8.2% response rate and a median
PFS of only 4.4 months. Overall these data indicate
that afatinib is modestly effective in patients with EGFR-
TKI acquired resistance and the best setting for using the
agent is in front-line only in patients harbouring EGFR
mutations.
In EGFR-TKI pretreatred patients, preclinical models
suggested that combination of afatinib with cetuxi-
mab, a monoclonal antibody against the extracellular
domain of the EGFR, is particularly effective in pres-
ence of acquired resistance [43].The superiority of the
combination is hypothesized to be due to cetuximab’s
ability to cause down-regulation of EGFR and afatinib’s
ability to block its kinase activity, leading to significantly
lower level EGFR pathway signaling, even with a T790M
mutation. Based on these findings, a large phase Ib/II
study showed a promising 32% response rate among the
53 individuals with EGFR-T790M mutation [44,45]. Al-
though cetuximab-afatinib combination showed promis-
ing results, current data do not justify its use outside
clinical trials.
Targeting a specific alteration of the EGFR
downstreamingsignalling
Recently, investigators have identified covalent pyrimidine
EGFR inhibitors, which are 30–100 fold more potent than
quinazoline based EGFR inhibitors against EGFR T790M
cells, and up to 100 fold less potent against wild type EGFR
cells, as CO-1686 and AP26113 [46].
CO-1686, an oral covalent TKI, has been investigated
in a phase I/II study [47], enrolling T790M-mutated
patients pretreated with first generation TKIs. Prelim-
inary results suggested a relevant activity and satisfac-
tory tolerability, with the absence of typical adverse
events derived from EGFR inhibition. AP26113, a
novel TKI that potently inhibits mutant activated
forms of ALK, EGFR and TKI-resistant forms includ-
ing T790M positive, is nowadays testing in a phase I
dose finding study [48] with initial evidence of activ-
ity in EGFR mutated patients progressed to prior TKI
therapy.
Considering the high selective target, this class of in-
hibitors could likely represent a real chance of treatment
for patients with EGFR-TKI acquired resistance, after
the necessary confirmation derived from large, prospect-
ive, randomized trials.Combinating the EGFR plus alternate pathways inhibition
Vascular endothelial growth factor (VEGF) pathway has
been extensively studied as therapeutic target in NSCLC.
Several studies demonstrated the existence of a cross-
talk between VEGF and EGFR pathways, being the EGFR
a regulator of VEGF expression, in turn associated with
resistance to EGFR inhibition [49,50]. Therefore, there is
a strong rationale for using strategies inhibiting both tar-
gets as the multi-targeted TKI agents XL647 and BMS-
690514.
XL647, an oral small-molecule inhibitor of EGFR,
VEGFR-2, HER2 and Ephrin type-B receptor 4 (EphB4),
in preclinical studies showed efficacy against EGFR-
driven tumors, including those harboring T790M [51].
However, a phase II trial enrolling patients with EGFR-
TKI acquired resistance, demonstrated a disappointing
3% RR, not supporting further investigation [52], Table 3.
At the same time, another phase II trial of first-line
XL647 in a population enriched for EGFR mutations
(i.e. lung adenocarcinoma, never-smokers, females, EGFR
mutated patients) (Table 2) showed a RR of 19.6% in the
overall population and a RR of 57% among the 14 patients
harbouring an activating EGFR mutation. These data sug-
gested that the efficacy of XL647 is confined to the EGFR
mutated population [53]. In a subsequent exploratory
study, Chmielecki et al. investigated the clinical character-
istics of eight patients with metastatic EGFR-mutant lung
adenocarcinoma who were treated first-line with XL647
and then progressed. The study showed that, among the 5
tumor samples collected at the time of XL647 failure, only
one harbored the T790M mutation and that three pa-
tients treated with second line erlotinib derived add-
itional long-term benefit from the EGFR TKI [54].
Overall, the study emphasize the potential role of XL647
as an agent that do not necessarily select for T790M-
mediated resistance and allow the sequential use of non-
cross-resistant EGFR TKIs.
BMS-690514, a reversible oral inhibitor of EGFR, HER-2
and −4, VEGFRs-1 to −3, showed antitumour activity in
tumour xenograft models and in cell lines containing the
EGFR T790M mutation, suggesting a role against erlotinib-
resistant tumours [55]. A phase I/II trial has recently evi-
denced a modest activity and disease control in both
erlotinib-naıve and erlotinib-resistant NSCLC patients [56].
A randomised phase II trial comparing BMS 690514 with
erlotinib is currently ongoing.
Conclusion
In the last years, the treatment of NSCLC has dramatic-
ally changed. Currently, the treatment’s choice is based
on a careful assessment of tumor histology and, most
importantly, of biological characteristics, specifically of
the EGFR and ALK status. EGFR mutations identify a
distinct subgroup of NSCLC which benefit from a first
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evidenced by several phase III trials. Second generation
TKIs are new agents currently under investigation with
the intent to improve the efficacy in the first line setting
and to provide a valid treatment option in the acquired re-
sistance setting. New inhibitors such as dacomitinib and
afatinib differ from first generation EGFR-TKIs because
they form irreversible link to the EGFR kinase domain
and inhibit other receptors (i.e. HER2 and HER4). The po-
tential superiority of dacomitinib versus erlotinib in KRAS
wild-type NSCLC is currently under investigation in a
large phase III trial. Afatinib demonstrated superiority ver-
sus standard chemotherapy in two phase III studies and
based on the results of the LUX LUNG 3 trial, Food and
Drug Administration has recently approved the drug for
the first-line treatment of patients with NSCLC whose tu-
mors harbored EGFR exon 19 deletions or exon 21
(L858R) substitution mutations as detected by an FDA-
approved test, specifically the therascreen EGFR RGQ
PCR Kit (QIAGEN). Subsequently, the European Com-
mittee for Medicinal Products for Human Use (CHMP)
adopted a positive opinion, recommending the granting of
a marketing authorisation for afatinib.
From the clinical point of view there are many ques-
tions about new EGFR-TKIs including efficacy and tox-
icity over erlotinib or gefitinib. At the present time there
is no phase III study directly comparing new versus old
EGFR-TKIs. Based on indirect comparison it seems that
new generation EGFR-TKIs produce a similar response
rate to erlotinib or gefitinib with a possible improvement
in terms of progression-free survival and with an in-
creased risk of side effects particularly skin rash and
diarrhea. Available data with afatinib in NSCLC with ac-
quired resistance to erlotinib or gefitinib indicate that
this agent is modestly effective in such setting and new
drugs and new strategies are urgently needed.
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